{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:22:50Z","timestamp":1791339770332,"version":"4.3.1"},"reference-count":61,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>von Willebrand factor (VWF) is a large adhesive multimeric protein involved in hemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein. A deficiency or defect of VWF can lead to von Willebrand disease (VWD) and cause bleeding. Conversely, an increase in VWF may create an environment that promotes thrombosis. ADAMS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), sometimes called VWF-cleaving protease, is primarily responsible for controlling the size of VWF. The most severe deficiency (&lt;10% of normal levels) of ADAMTS-13 arises in thrombotic thrombocytopenic purpura, a condition characterized by the presence of ultralarge VWF and clinically resulting in enhanced risk of thrombosis. However, ADAMTS-13 deficiency may result from other pathological processes. Of relevance is the recent finding that COVID-19 (coronavirus disease 2019) is associated with both increased levels and activity of VWF as well as generally decreased (or occasionally normal) activity levels of ADAMTS-13. Thus, in COVID-19 there is an alteration in the VWF\/ADAMTS-13 axis, most often described by increased VWF\/ADAMTS-13 ratio (or reduced ADAMTS-13\/VWF ratio). COVID-19 is also associated with high prothrombotic risk. Thus, the imbalance of VWF and ADAMTS-13 in COVID-19 may be providing a milieu that promotes (micro)thrombosis, in a clinical picture resembling a secondary thrombotic microangiopathy in some patients. This review therefore assesses the literature on VWF, ADAMTS-13, and COVID-19. Whenever reported in COVID-19, VWF has always been identified as raised (compared with normal reference ranges or control populations). Reports have included VWF level (i.e., VWF antigen) and in some cases one or more VWF \u201cactivity\u201d (e.g., collagen binding; platelet glycoprotein Ib [GPIb] binding, using ristocetin cofactor or more modern versions including VWF:GPIbR [recombinant] and VWF:GPIbM [mutant]). Whenever reported, ADAMTS-13 has been reported as \u201cnormal\u201d or reduced; however, it should be recognized that \u201cnormal\u201d levels may still identify a relative reduction in individual cases. Some reports also discuss the raised VWF\/ADAMTS-13 (or reduced ADAMTS-13\/VWF) ratio, but very few provide actual numerical data.<\/jats:p>","DOI":"10.1055\/s-0041-1727282","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T01:20:43Z","timestamp":1619227243000},"page":"400-418","source":"Crossref","is-referenced-by-count":103,"title":["Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis"],"prefix":"10.1055","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[{"name":"Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-338X","authenticated-orcid":false,"given":"Brandon Michael","family":"Henry","sequence":"additional","affiliation":[{"name":"Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"01","key":"ref1","first-page":"17","article-title":"Von Willebrand factor: form for function","volume":"40","author":"A Yee","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref2","first-page":"338","article-title":"Monitoring therapy during treatment of von Willebrand disease","volume":"43","author":"E J Favaloro","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0037-1605564","article-title":"von Willebrand factor and venous thromboembolism: pathogenic link and therapeutic implications","volume":"44","author":"P Calabr\u00f2","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0040-1708541","article-title":"Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults","volume":"46","author":"R Blennerhassett","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/ckj\/sfz040","article-title":"An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy","volume":"12","author":"C Aigner","year":"2019","journal-title":"Clin Kidney J"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis","volume":"18","author":"M Panigada","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence","volume":"142","author":"J Poissy","year":"2020","journal-title":"Circulation"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"J Helms","year":"2020","journal-title":"Intensive Care Med"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study","volume":"7","author":"G Goshua","year":"2020","journal-title":"Lancet Haematol"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.7861\/clinmed.2020-0346","article-title":"Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19?","volume":"20","author":"E E Ladikou","year":"2020","journal-title":"Clin Med (Lond)"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.120.048925","article-title":"Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study","volume":"142","author":"P Masi","year":"2020","journal-title":"Circulation"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12872-020-01658-z","article-title":"Implications of ABO blood group in hypertensive patients with covid-19","volume":"20","author":"C Sardu","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1111\/jth.15067","article-title":"Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19","volume":"18","author":"A Rauch","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.thromres.2020.08.030","article-title":"Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients","volume":"196","author":"D J Hoechter","year":"2020","journal-title":"Thromb Res"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1161\/ATVBAHA.120.315175","article-title":"platelets promote thromboinflammation in SARS-CoV-2 pneumonia","volume":"40","author":"F Taus","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11239-020-02318-x","article-title":"COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis","volume":"51","author":"B E Fan","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"102560","DOI":"10.1016\/j.jaut.2020.102560","article-title":"Complement activation and endothelial perturbation parallel COVID-19 severity and activity","volume":"116","author":"M Cugno","year":"2021","journal-title":"J Autoimmun"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.17273","article-title":"Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation","volume":"192","author":"S E Ward","year":"2021","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02339-6","article-title":"Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?","author":"F Ruberto","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/ALN.0000000000003685","article-title":"Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients","volume":"134","author":"C Heinz","year":"2021","journal-title":"Anesthesiology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-020-09762-6","article-title":"Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality","author":"A Philippe","year":"2021","journal-title":"Angiogenesis"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/cells10010186","article-title":"ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients","volume":"10","author":"A G Vassiliou","year":"2021","journal-title":"Cells"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1055\/s-0040-1722612","article-title":"A matter of caution: coagulation parameters in COVID-19 do not differ from patients with ruled-out SARS-CoV-2 infection in the emergency department","volume":"5","author":"W Bauer","year":"2021","journal-title":"TH Open"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.thromres.2020.07.034","article-title":"A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19","volume":"193","author":"N Martinelli","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-020-09753-7","article-title":"Microvascular dysfunction in COVID-19: the MYSTIC study","volume":"24","author":"A Rovas","year":"2021","journal-title":"Angiogenesis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X20964089","article-title":"Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: a case series","author":"A Alharthy","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1111\/ijlh.13244","article-title":"Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2","volume":"42","author":"A Huisman","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11739-020-02394-0","article-title":"Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients","volume":"15","author":"M Bazzan","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1055\/s-0040-1713400","article-title":"Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink","volume":"120","author":"N Morici","year":"2020","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jth.15043","article-title":"In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation","volume":"18","author":"A Blasi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1055\/s-0040-1716379","article-title":"Reduction of ADAMTS13 levels predicts mortality in SARS-CoV-2 patients","volume":"4","author":"G L Tiscia","year":"2020","journal-title":"TH Open"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"e0194","DOI":"10.1097\/CCE.0000000000000194","article-title":"Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation","volume":"2","author":"D D Fraser","year":"2020","journal-title":"Crit Care Explor"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.20.20215608","article-title":"Evidence for secondary thrombotic microangiopathy in COVID-19","author":"J M Sweeney","year":"2020","journal-title":"medRxiv"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"106519","DOI":"10.1016\/j.dib.2020.106519","article-title":"Prothrombotic hemostasis disturbances in patients with severe COVID-19: individual daily data","volume":"33","author":"M Hardy","year":"2020","journal-title":"Data Brief"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jth.15191","article-title":"The ADAMTS13-von Willebrand factor axis in COVID-19 patients","volume":"19","author":"I Mancini","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13415","article-title":"ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy","author":"B M Henry","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.140","article-title":"Plasma exchange for COVID-19 thrombo-inflammatory disease","author":"N Arulkumaran","year":"2020","journal-title":"EJHaem"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bjh.17216","article-title":"von Willebrand factor\/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients","volume":"192","author":"M Delrue","year":"2021","journal-title":"Br J Haematol"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1002\/ctm2.268","article-title":"Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVID-19 outcomes","volume":"11","author":"M P Fern\u00e1ndez-P\u00e9rez","year":"2021","journal-title":"Clin Transl Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13476","article-title":"Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients","author":"M Rodr\u00edguez Rodr\u00edguez","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000001007","article-title":"Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU","author":"R De Jongh","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000998","article-title":"Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study","author":"R De Cristofaro","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/rth2.12462","article-title":"Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality","volume":"5","author":"F A von Meijenfeldt","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/jcm10040671","article-title":"No evidence for classic thrombotic microangiopathy in COVID-19","volume":"10","author":"T Falter","year":"2021","journal-title":"J Clin Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.02.008","article-title":"ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19","author":"T Pascreau","year":"2021","journal-title":"Thromb Res"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1097\/CCM.0000000000004918","article-title":"von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019","volume":"49","author":"A AN Doevelaar","year":"2021","journal-title":"Crit Care Med"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1055\/s-0040-1713735","article-title":"Navigating the myriad of von Willebrand factor assays","volume":"40","author":"E J Favaloro","year":"2020","journal-title":"Hamostaseologie"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.thromres.2015.12.010","article-title":"Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease","volume":"141","author":"E J Favaloro","year":"2016","journal-title":"Thromb Res"},{"issue":"05","key":"ref50","first-page":"1009","article-title":"Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease","volume":"104","author":"E J Favaloro","year":"2010","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ijlh.13107","article-title":"Semi-automated von Willebrand factor multimer assay for von Willebrand disease: further validation, benefits and limitations","volume":"41","author":"S Oliver","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/rth2.12392","article-title":"Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies","volume":"4","author":"E J Favaloro","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/hae.13957","article-title":"Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies","volume":"26","author":"E J Favaloro","year":"2020","journal-title":"Haemophilia"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity","volume":"19","author":"E J Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1515\/cclm-2020-0573","article-title":"Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation","volume":"58","author":"E J Favaloro","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mayocp.2020.10.031","article-title":"Coronavirus disease 2019-associated coagulopathy","volume":"96","author":"G Lippi","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-0040-1712156","article-title":"Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both","volume":"46","author":"M Levi","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1055\/s-0040-1712155","article-title":"SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: Is it pulmonary thrombosis or pulmonary embolism?","volume":"46","author":"J Thachil","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1055\/s-0040-1710337","article-title":"Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism","volume":"46","author":"S Schulman","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study","volume":"28","author":"D Annane","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.clim.2020.108555","article-title":"Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19","volume":"219","author":"J Laurence","year":"2020","journal-title":"Clin Immunol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"V Giudice","year":"2020","journal-title":"Front Pharmacol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1727282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:43:25Z","timestamp":1622587405000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1727282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":61,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1727282","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}